Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-744-1340
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.10 million
Profitability
Miscellaneous
Employees56
OptionableOptionable
Syros Pharmaceuticals (NASDAQ:SYRS) Frequently Asked Questions
What is Syros Pharmaceuticals' stock symbol?
Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."
How were Syros Pharmaceuticals' earnings last quarter?
Syros Pharmaceuticals Inc (NASDAQ:SYRS) announced its quarterly earnings data on Friday, August, 10th. The company reported ($0.43) EPS for the quarter, topping the Zacks' consensus estimate of ($0.50) by $0.07. The business earned $0.38 million during the quarter, compared to the consensus estimate of $1.33 million. View Syros Pharmaceuticals' Earnings History.
When is Syros Pharmaceuticals' next earnings date?
What price target have analysts set for SYRS?
6 Wall Street analysts have issued 12 month price targets for Syros Pharmaceuticals' shares. Their forecasts range from $10.00 to $33.00. On average, they anticipate Syros Pharmaceuticals' share price to reach $16.60 in the next year. This suggests a possible upside of 140.2% from the stock's current price. View Analyst Price Targets for Syros Pharmaceuticals.
What is the consensus analysts' recommendation for Syros Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syros Pharmaceuticals.
What are Wall Street analysts saying about Syros Pharmaceuticals stock?
Here are some recent quotes from research analysts about Syros Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company's product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. " (11/6/2018)
- 2. HC Wainwright analysts commented, "Our price target of $10/share ($3.38 from tamibarotene + $2.35 from platform + $3.83 in cash) is based on a discounted cash flow analysis (2018-2027) using a 12% discount rate and 1% growth rate, in line with the expected discount and growth parameters of a development-stage oncology company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) smaller than anticipated commercial opportunity due to market size, competition, and pricing." (8/8/2018)
Has Syros Pharmaceuticals been receiving favorable news coverage?
Media coverage about SYRS stock has trended somewhat positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Syros Pharmaceuticals earned a news sentiment score of 1.1 on InfoTrie's scale. They also gave news stories about the company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an effect on the company's share price in the near term.
Who are some of Syros Pharmaceuticals' key competitors?
Some companies that are related to Syros Pharmaceuticals include Homology Medicines (FIXX), CannTrust (CNTTF), Athenex (ATNX), ImmunoGen (IMGN), CytomX Therapeutics (CTMX), Radius Health (RDUS), Apellis Pharmaceuticals (APLS), G1 Therapeutics (GTHX), Inflarx (IFRX), Intra-Cellular Therapies (ITCI), Y-mAbs Therapeutics (YMAB), Evolus (EOLS), Arvinas (ARVN), Omeros (OMER) and ANI Pharmaceuticals (ANIP).
Who are Syros Pharmaceuticals' key executives?
Syros Pharmaceuticals' management team includes the folowing people:
- Dr. Nancy A. Simonian, Pres, CEO & Director (Age 58)
- Dr. Richard A. Young, Scientific Founder, Member of Scientific Advisory Board & Director (Age 65)
- Dr. David A. Roth, Chief Medical Officer (Age 56)
- Dr. Jeremy P. Springhorn, Chief Bus. Officer (Age 57)
- Dr. Nathanael S. Gray, Scientific Founder & Member of Scientific Advisory Board
When did Syros Pharmaceuticals IPO?
(SYRS) raised $60 million in an initial public offering (IPO) on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Who are Syros Pharmaceuticals' major shareholders?
Syros Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.90%), Northern Trust Corp (0.91%), Geode Capital Management LLC (0.74%), Dimensional Fund Advisors LP (0.73%), Connor Clark & Lunn Investment Management Ltd. (0.36%) and Assenagon Asset Management S.A. (0.27%). Company insiders that own Syros Pharmaceuticals stock include Colleen Elizabeth Desimone, Eric R Olson, Jeremy P Springhorn, Richard A Young and Srinivas Akkaraju. View Institutional Ownership Trends for Syros Pharmaceuticals.
Which major investors are selling Syros Pharmaceuticals stock?
Which major investors are buying Syros Pharmaceuticals stock?
SYRS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Dimensional Fund Advisors LP, Assenagon Asset Management S.A., D. E. Shaw & Co. Inc., Geode Capital Management LLC, Alps Advisors Inc., Bank of America Corp DE and Rhumbline Advisers. Company insiders that have bought Syros Pharmaceuticals stock in the last two years include Jeremy P Springhorn and Srinivas Akkaraju. View Insider Buying and Selling for Syros Pharmaceuticals.
How do I buy shares of Syros Pharmaceuticals?
Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Syros Pharmaceuticals' stock price today?
One share of SYRS stock can currently be purchased for approximately $6.91.
How big of a company is Syros Pharmaceuticals?
Syros Pharmaceuticals has a market capitalization of $232.52 million and generates $1.10 million in revenue each year. The company earns $-54,010,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis. Syros Pharmaceuticals employs 56 workers across the globe.
What is Syros Pharmaceuticals' official website?
How can I contact Syros Pharmaceuticals?
Syros Pharmaceuticals' mailing address is 620 Memorial Drive Suite 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected]
MarketBeat Community Rating for Syros Pharmaceuticals (NASDAQ SYRS)
MarketBeat's community ratings are surveys of what our community members think about Syros Pharmaceuticals and other stocks. Vote "Outperform" if you believe SYRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
